Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$0.73 USD
-0.03 (-4.01%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $0.72 -0.01 (-1.30%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MCRB 0.73 -0.03(-4.01%)
Will MCRB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MCRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MCRB
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
MCRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for MCRB
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Seres announces completion of patient enrollment for SERS-155 Phase 1b cohort 2
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024